Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Investigations of pravastatin for the prevention of preeclampsia
(Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - March 25, 2023 Category: OBGYN Authors: Maged M. Costantine, Rebecca G. Clifton, George R Saade Source Type: research
Prevention of recurrent preeclampsia in high-risk pregnancies: Is it time for a paradigm shift?
Statins are the class of drugs traditionally used to treat hyperlipidemia. Owing to the association of preeclampsia and high maternal hyperlipidemia and its ability to reverse an angiogenic imbalance and correct endothelial dysfunction, pravastatin (hydrophilic statin) has been used to prevent or treat preeclampsia during pregnancy. Although pravastatin has been demonstrated to have preventative effects in preeclampsia model mice without negatively affecting offspring outcomes, and the Food and Drug Administration removed the “Pregnancy Category X” label for statins, their safety concerning the fetus is still of concer...
Source: American Journal of Obstetrics and Gynecology - March 25, 2023 Category: OBGYN Authors: Xiao-Mei Lin, Dong-Zhi Li Tags: Letter to the Editors Source Type: research
